6-(2-(二甲氨基)乙氧基)吡啶-2-胺 | 400775-62-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(2-(二甲氨基)乙氧基)吡啶-2-胺
• 英文名称: 6-(2-(dimethylamino)ethoxy)pyridin-2-amine
• 英文别名: 6-[2-(dimethylamino)ethoxy]pyridin-2-amine
• CAS: 400775-62-4
• 化学式: C₉H₁₅N₃O
• 分子量: 181.238
• InChiKey: WPPCTJBZEZBLRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  51.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(2-(二甲氨基)乙氧基)吡啶-2-胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 、 醋酸异丙酯 为溶剂， 反应 3.5h， 生成 1-(4-((2-((6-(2-(dimethylamino)ethoxy)pyridin-2-yl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)-3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)urea
  参考文献：
  名称：

  [EN] DIARYL UREA DERIVATIVES AS P38 MAP KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE

  摘要：

  公开号：

  WO2014033447A3
• 作为产物：
  描述：

  2-氨基-6-氯吡啶 、 N,N-二甲基乙醇胺 在 sodium 作用下， 反应 4.0h， 以791 mg的产率得到6-(2-(二甲氨基)乙氧基)吡啶-2-胺
  参考文献：
  名称：

  [EN] DIARYL UREA DERIVATIVES AS P38 MAP KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE

  摘要：

  公开号：

  WO2014033447A3

文献信息

• Substituted fused pyrroleoximes and fused pyrazoleoximes
  申请人：——

  公开号：US20020128236A1

  公开（公告）日：2002-09-12

  Disclosed are compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  揭示了公式1的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2在此处定义。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或逆拮抗剂，或者是GABAA脑受体的激动剂、拮抗剂或逆拮抗剂的前药，因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆的诊断和治疗中非常有用。还披露了包括包装的药物组合物在内的药物组合物。
• Thiazolyl urea compounds and methods of uses
  申请人：——

  公开号：US20020193405A1

  公开（公告）日：2002-12-19

  Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的新型尿素化合物对预防和治疗疾病有效，如细胞增殖或凋亡介导的疾病。该发明涵盖了新型化合物、类似物、前药和其药用可接受的盐，以及用于预防和治疗中风、癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在这些过程中有用的中间体。
• Urea compounds and methods of uses
  申请人：——

  公开号：US20020173507A1

  公开（公告）日：2002-11-21

  Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的新型尿素化合物对预防和治疗疾病有效，例如细胞增殖或凋亡介导的疾病。该发明涵盖了新型化合物、类似物、前药和其药用可接受的盐、预防和治疗涉及中风、癌症等疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备此类化合物的过程以及在此类过程中有用的中间体。
• [EN] THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSES DE THIAZOLYL UREE POUR LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2003070727A1

  公开（公告）日：2003-08-28

  Selected thiazolyl urea compounds of formula (VI) are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  公式（VI）的选定噻唑基脲类化合物对预防和治疗细胞增殖或凋亡介导的疾病有效。本发明涵盖新的化合物、类似物、前药和其药学上可接受的盐、药物组合物和预防和治疗中风、癌症等疾病及其他疾病或情况的方法。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes
  申请人：Maynard George

  公开号：US20080032975A1

  公开（公告）日：2008-02-07

  Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  本发明涉及以下式的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2的定义如下。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药，因此可用于诊断和治疗焦虑症、抑郁症、唐氏综合征、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆。还公开了包括包装的药物组合物在内的制药组合物。